Gary Chan

3.2k total citations · 2 hit papers
58 papers, 2.4k citations indexed

About

Gary Chan is a scholar working on Dermatology, Genetics and Epidemiology. According to data from OpenAlex, Gary Chan has authored 58 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Dermatology, 17 papers in Genetics and 15 papers in Epidemiology. Recurrent topics in Gary Chan's work include Dermatology and Skin Diseases (19 papers), Inflammatory Bowel Disease (17 papers) and Asthma and respiratory diseases (11 papers). Gary Chan is often cited by papers focused on Dermatology and Skin Diseases (19 papers), Inflammatory Bowel Disease (17 papers) and Asthma and respiratory diseases (11 papers). Gary Chan collaborates with scholars based in United States, Canada and United Kingdom. Gary Chan's co-authors include Nervin Lawendy, Chinyu Su, Chudy I. Nduaka, Sriram Krishnaswami, Bruce E. Sands, Julián Panés, Michele Moscariello, Hernán Valdez, Marco DiBonaventura and Geert D’Haens and has published in prestigious journals such as SHILAP Revista de lepidopterología, Gastroenterology and Gut.

In The Last Decade

Gary Chan

56 papers receiving 2.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials

2017 296 citations Julián Panés, William J. Sandborn et al. Gut profile →
Efficacy and Safety of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis

2020 289 citations Jonathan I. Silverberg, Eric L. Simpson et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Gary Chan United States	22	870	681	595	564	562	58	2.4k
B. Randazzo United States	29	558 0.6×	565 0.8×	2.7k 4.6×	1.7k 3.0×	461 0.8×	71	3.9k
Howard Sofen United States	27	298 0.3×	662 1.0×	2.6k 4.4×	2.0k 3.6×	347 0.6×	96	3.9k
Yasmine Wasfi United States	19	225 0.3×	528 0.8×	2.8k 4.6×	1.7k 3.1×	263 0.5×	40	3.2k
Lisa T. Dooley United States	14	417 0.5×	1.3k 1.9×	5.4k 9.1×	2.9k 5.1×	407 0.7×	15	6.1k
Jean Claude Roujeau France	12	125 0.1×	1.9k 2.8×	471 0.8×	1.1k 2.0×	660 1.2×	12	3.8k
Taeko Ishii Japan	18	83 0.1×	1.0k 1.5×	629 1.1×	251 0.4×	118 0.2×	54	2.0k
Yaung‐Kaung Shen United States	21	169 0.2×	971 1.4×	2.6k 4.4×	1.4k 2.5×	187 0.3×	37	3.0k
Wojciech Niezychowski United States	11	1.9k 2.1×	422 0.6×	686 1.2×	56 0.1×	1.2k 2.2×	31	2.5k
Terence Rooney United States	28	107 0.1×	2.9k 4.2×	806 1.4×	197 0.3×	208 0.4×	53	3.9k
Scott W. Baumgartner United States	16	159 0.2×	1.4k 2.0×	766 1.3×	73 0.1×	124 0.2×	18	2.5k

Countries citing papers authored by Gary Chan

Since Specialization

Citations

This map shows the geographic impact of Gary Chan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gary Chan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gary Chan more than expected).

Fields of papers citing papers by Gary Chan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gary Chan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gary Chan. The network helps show where Gary Chan may publish in the future.

Co-authorship network of co-authors of Gary Chan

This figure shows the co-authorship network connecting the top 25 collaborators of Gary Chan. A scholar is included among the top collaborators of Gary Chan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gary Chan. Gary Chan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Silverberg, Jonathan I., Eric L. Simpson, Andrew Pink, et al.. (2025). Switching from Dupilumab to Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis: A Post Hoc Analysis of Efficacy After Treatment With Dupilumab in JADE DARE. Dermatology and Therapy. 15(2). 367–380. 1 indexed citations

Wang, X., Martin E. Dowty, Vu Le, et al.. (2024). Assessment of the Effects of Abrocitinib on the Pharmacokinetics of Probe Substrates of Cytochrome P450 1A2, 2B6 and 2C19 Enzymes and Hormonal Oral Contraceptives in Healthy Individuals. European Journal of Drug Metabolism and Pharmacokinetics. 49(3). 367–381. 3 indexed citations

Reich, Kristian, Jonathan I. Silverberg, Kim Papp, et al.. (2023). Abrocitinib effect on patient‐reported outcomes in patients with moderate‐to‐severe atopic dermatitis: Results from phase 3 studies, including the long‐term extension JADE EXTEND study. Journal of the European Academy of Dermatology and Venereology. 37(10). 2047–2055. 5 indexed citations

Reich, Kristian, Jonathan I. Silverberg, Kim Papp, et al.. (2023). Abrocitinib efficacy and safety in patients with moderate‐to‐severe atopic dermatitis: Results from phase 3 studies, including the long‐term extension JADE EXTEND study. Journal of the European Academy of Dermatology and Venereology. 37(10). 2056–2066. 20 indexed citations

Guttman‐Yassky, Emma, Paola Facheris, Ester Del Duca, et al.. (2023). Effect of abrocitinib on skin biomarkers in patients with moderate‐to‐severe atopic dermatitis. Allergy. 79(5). 1258–1270. 17 indexed citations

Gooderham, Melinda, Michael R. Ardern‐Jones, Emma Guttman‐Yassky, et al.. (2023). Efficacy and safety of abrocitinib in patients with moderate‐to‐severe atopic dermatitis with prior exposure to oral systemic immunosuppressants or biologic therapies: A post hoc analysis of the JADE clinical trials. SHILAP Revista de lepidopterología. 2(4). 753–763. 1 indexed citations

Yosipovitch, Gil, Melinda Gooderham, Sonja Ständer, et al.. (2023). Interpreting the Relationship Among Itch, Sleep, and Work Productivity in Patients with Moderate-to-Severe Atopic Dermatitis: A Post Hoc Analysis of JADE MONO-2. American Journal of Clinical Dermatology. 25(1). 127–138. 7 indexed citations

Alexis, Andrew, Jonathan I. Silverberg, Zakiya P. Rice, et al.. (2023). Abrocitinib efficacy and safety in moderate-to-severe atopic dermatitis by race, ethnicity, and Fitzpatrick skin type. Annals of Allergy Asthma & Immunology. 132(3). 383–389.e3. 2 indexed citations

Simpson, Eric L., Audrey Nosbaum, Kevin Winthrop, et al.. (2023). Safety of Abrocitinib in 3582 Patients With Moderate-to-Severe Atopic Dermatitis With Over 900 Patients Exposed for Almost 2 Years. SKIN The Journal of Cutaneous Medicine. 7(2). s150–s150. 1 indexed citations

10.

Thyssen, Jacob P., Anthony Bewley, Sonja Ständer, et al.. (2023). Abrocitinib Provides Rapid and Sustained Improvement in Skin Pain and Is Associated with Improved Quality of Life Outcomes in Adult and Adolescent Patients with Moderate-to-Severe Atopic Dermatitis. Dermatology. 240(2). 243–253. 2 indexed citations

11.

Panaccione, Remo, John D. Isaacs, Lea Ann Chen, et al.. (2020). Characterization of Creatine Kinase Levels in Tofacitinib-Treated Patients with Ulcerative Colitis: Results from Clinical Trials. Digestive Diseases and Sciences. 66(8). 2732–2743. 11 indexed citations

12.

Sands, Bruce E., Alessandro Armuzzi, John K. Marshall, et al.. (2019). Efficacy and safety of tofacitinib dose de‐escalation and dose escalation for patients with ulcerative colitis: results from OCTAVE Open. Alimentary Pharmacology & Therapeutics. 51(2). 271–280. 65 indexed citations

13.

Sandborn, William J., Julián Panés, Geert D’Haens, et al.. (2018). Safety of Tofacitinib for Treatment of Ulcerative Colitis, Based on 4.4 Years of Data From Global Clinical Trials. Clinical Gastroenterology and Hepatology. 17(8). 1541–1550. 193 indexed citations

14.

Panés, Julián, William J. Sandborn, Stefan Schreiber, et al.. (2017). Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials. Gut. 66(6). 1049–1059. 296 indexed citations breakdown →

15.

Ng, Tze Pin, Ma Shwe Zin Nyunt, Lei Feng, et al.. (2016). Multi-domains lifestyle interventions reduces depressive symptoms among frail and pre-frail older persons: Randomized controlled trial. The journal of nutrition health & aging. 21(8). 918–926. 48 indexed citations

16.

Krishnaswami, Sriram, M. Boy, Vincent Chow, & Gary Chan. (2014). Safety, tolerability, and pharmacokinetics of single oral doses of tofacitinib, a Janus kinase inhibitor, in healthy volunteers. Clinical Pharmacology in Drug Development. 4(2). 83–88. 35 indexed citations

17.

Robillard, Kevin R., et al.. (2014). Role of CNS Transporters in the Pharmacotherapy of HIV-1 Associated Neurological Disorders. Current Pharmaceutical Design. 20(10). 1543–1563. 4 indexed citations

18.

Krishnaswami, Sriram, Vincent Chow, M. Boy, Cunshan Wang, & Gary Chan. (2013). Pharmacokinetics of tofacitinib, a janus kinase inhibitor, in patients with impaired renal function and end‐stage renal disease. The Journal of Clinical Pharmacology. 54(1). 46–52. 44 indexed citations

19.

Quaedackers, Monique E., Marcia M. L. Kho, Wendy M. Mol, et al.. (2012). Pharmacodynamic Analysis of Tofacitinib and Basiliximab in Kidney Allograft Recipients. Transplantation. 94(5). 465–472. 15 indexed citations

20.

Weimar, Willem, Robert S. Gaston, Daniel C. Brennan, et al.. (2008). Phase 1 Dose-Escalation Study of CP-690 550 in Stable Renal Allograft Recipients: Preliminary Findings of Safety, Tolerability, Effects on Lymphocyte Subsets and Pharmacokinetics. American Journal of Transplantation. 8(8). 1711–1718. 59 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact